RAG-17

N/A

Report date: 2026/02/09 20:01:27
NME

Base Information

Drug NameRAG-17
Drug Alias NameRAG-17RD-12500
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionSuperoxide dismutase inhibitors
TargetsSuperoxide dismutase
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRactigen Therapeutics (Nantong) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesRactigen Therapeutics (Nantong) Co LtdBeijing Tiantan Hospital, Capital Medical University
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A